Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Thymosin Alpha-1 (TA1) is a immune peptide, at the approved (asia, latin america) stage in the published literature. Natural peptide produced by the thymus that modulates immune function. Approved in multiple countries for hepatitis and as cancer adjuvant.
Natural peptide produced by the thymus that modulates immune function. Approved in multiple countries for hepatitis and as cancer adjuvant.
| Research Status | Approved (Asia, Latin America) |
|---|---|
| Half-Life | 2 hours |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 1.6 mg twice weekly |
Enhances T-cell function, dendritic cell maturation, and overall immune surveillance.
Natural peptide produced by the thymus that modulates immune function. Approved in multiple countries for hepatitis and as cancer adjuvant.
Enhances T-cell function, dendritic cell maturation, and overall immune surveillance.
Thymosin Alpha-1 is at the following stage in the published literature: Approved (Asia, Latin America). All information is for research and educational purposes only.
Reported half-life: 2 hours.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.